Is Dilactone actinomycin D acid Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Dilactone actinomycin D acid? Is Dilactone actinomycin D acid safe for nursing mother and child? Does Dilactone actinomycin D acid extracts into breast milk? Does Dilactone actinomycin D acid has any long term or short term side effects on infants? Can Dilactone actinomycin D acid influence milk supply or can Dilactone actinomycin D acid decrease milk supply in lactating mothers?
Dilactone actinomycin D acid lactation summary
- DrLact safety Score for Dilactone actinomycin D acid is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Dilactone actinomycin D acid may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Dilactone actinomycin D acid may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Dilactone actinomycin D acid .
- Usage of Dilactone actinomycin D acid is in contradiction to breastfeeding hence if it is must to use Dilactone actinomycin D acid and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Dilactone actinomycin D acid usage in lactation
Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 10 days of pumping-and-dumping.
Answer by DrLact: About Dilactone actinomycin D acid usage in lactation
No information is available on the use of Dilactone actinomycin D acid during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during Dilactone actinomycin D acid therapy and for 14 days after the last dose.
Alternate Drugs
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Dactinomycin(Dangerous)
Tamoxifen(Dangerous)
Ipilimumab(Unsafe)
Mitoxantrone(Dangerous)
Cetuximab(Unsafe)
Mercaptopurine(Safe)
Carboplatin(Dangerous)
Gemcitabine(Dangerous)
Paclitaxel(Dangerous)
Nivolumab(Unsafe)
Hydroxyurea(Low Risk)
Fluorouracil(Dangerous)
Vinblastine(Dangerous)
Etoposide(Dangerous)
Alemtuzumab(Low Risk)
Docetaxel(Dangerous)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Rituximab(Low Risk)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Cyclophosphamide(Dangerous)
Bevacizumab(Low Risk)
Dacarbazine(Dangerous)
Cisplatin(Unsafe)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Letrozole(Dangerous)
Imatinib(Unsafe)
Erlotinib(Unsafe)
Exemestane(Dangerous)
Dasatinib(Unsafe)
Azelaic Acid(Safe)
Nilotinib(Unsafe)
Dactinomycin(Dangerous)
Vincristine(Dangerous)
Dactinomycin(Dangerous)
Fusidic Acid(Safe)
Dactinomycin(Dangerous)